Hawaii Bio completes West Nile study dosing
Honolulu, USA-based Hawaii Biotech has completed the Phase I dosing of 24 healthy individuals with its HBV-002 West Nile virus vaccine.
Chief executive Elliot Parks said that preliminary safety results and immunologic data from the 24 subjects treated with three doses of the vaccine will be available early in 2009, with complete results expected by the following third quarter.
The firm's vaccine affiliate Acuvax, which was formerly known as Avantogen, designed the sub-unit vaccine with high fidelity to the native viral antigen in order to provide protective immunity to the recipients. The drug is non-replicating and designed to be safer than live-attenuated vaccines.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Today's issue
Company Spotlight
| Headless Content Management with Blaze